The Week of

Alamar Biosciences announced the launch of its NULISAseq Neuro 220 panel, a new research tool that allows scientists to measure over 200 proteins linked to brain diseases from a single sample.

The panel is designed to study complex neurological conditions like Alzheimer’s and Parkinson’s by capturing a wide range of biological signals, such as inflammation, neuron damage, and disease progression, all at once.

What makes it notable is its high sensitivity and broad coverage, which enable researchers to detect even very small amounts of these proteins, providing a clearer, earlier picture of what’s happening in the brain. Check it out: https://alamarbio.com/alamar-biosciences-launches-nulisaseq-neuro-220-panel-to-advance-neurodegenerative-disease-research/

Aspen Neuroscience announced positive 12-month results from its ASPIRO clinical trial, which is testing a personalized cell therapy for Parkinson’s disease.

The treatment works by taking a patient’s own cells, turning them into dopamine-producing brain cells, and implanting them into the brain to replace the cells that Parkinson’s destroys.

After one year, the data showed the therapy was safe, well-tolerated, and showed early signs of improving symptoms. Here’s more: https://aspenneuroscience.com/aspen-neuroscience-announces-positive-12-month-data-from-its-aspiro-clinical-trial-in-a-late-breaking-oral-presentation-at-t/

Researchers at Duke Health developed a simple nasal swab test that can detect early biological signs of Alzheimer’s disease, even before symptoms appear.

The test works by collecting cells from deep inside the nose, where smell-related neurons live. These cells are closely connected to the brain and can show early changes linked to Alzheimer’s. Check it out: https://www.nature.com/articles/s41467-026-70099-7

Did you know that Alzheimer’s was discovered in 1906 by a German physician named Alois Alzheimer?  

Alzheimer studied a patient, Auguste Deter, who had been experiencing severe memory loss, confusion, and hallucinations. After she passed away, he examined her brain to understand what caused her symptoms.

What he found were two unusual features: clumps of protein (now called amyloid plaques) and twisted fibers inside brain cells (neurofibrillary tangles).

Those two markers are still what scientists look for today.

You can read more about Alois Alzheimer here: https://www.alzint.org/about/dementia-facts-figures/types-of-dementia/alzheimers-disease/alois-alzheimer/